Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 36, Issue 5, Pages 1124-1135Publisher
WILEY
DOI: 10.1002/eji.200535443
Keywords
cancer vaccine; carrier; cytotoxic T lymphocytes; dendritic cell; tumor immunity
Categories
Ask authors/readers for more resources
The non-toxic B-subunit of Shiga toxin (STxB) interacts with the glycolipid Gb(3), which is preferentially expressed on dendritic cells (DC) and B cells. After administration of STxB chemically coupled to OVA (STxB-OVA) in mice, we showed that the immunodominant OVA(257-264) peptide restricted by K-b molecules is specifically presented by CD11c(+)CD8 alpha(-) DC, some of them displaying a mature phenotype. Using mice carrying a transgene encoding a diphtheria toxin receptor (DTR) under the control of the murine CD11c promoter, which allows inducible ablation of DC, we showed that DC are required for efficient priming of CTL after STxB-OVA vaccination. Immunization of mice with STxB-OVA induced OVA-specific CD8(+) T cells detected ex vivo; these cells were long lasting, since they could be detected even 91 days after the last immunization and were composed of both central and memory T cells. Vaccination of mice with STxB-OVA and STxB coupled to E7, a protein derived from HPV16, inhibited tumor growth in prophylactic and therapeutic experiments. This effect was mainly mediated by CD8+ T cells. STxB therefore appears to be a powerful carrier directly targeting DC in vivo, resulting in a strong and durable CTL response associated with tumor protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available